Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (NASDAQ: GANX) is a pioneering biotechnology company committed to the discovery and development of novel small molecule therapeutics. Specializing in addressing rare genetic diseases, Gain Therapeutics focuses on orphan diseases caused by inborn errors of metabolism. With a strong emphasis on lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology, the company's innovative approach aims to provide solutions where there is a high unmet medical need.
At the forefront of Gain Therapeutics' pipeline is GT-02287, a promising clinical-stage product candidate targeting GBA1 Parkinson's disease. Currently in Phase 1 clinical trials, GT-02287 is designed to be a disease-modifying treatment. It functions as an allosteric protein modulator to restore the activity of the lysosomal enzyme glucocerebrosidase (GCase), tackling the underlying cause of disease rather than just alleviating symptoms.
The company's proprietary Magellan™ platform leverages AI-supported structural biology and advanced algorithms to discover novel allosteric binding sites on disease-implicated proteins. This innovative computational technology identifies potential small molecules that can bind to these sites, offering new avenues for therapeutic development. Magellan builds upon Gain’s original SEE-Tx® platform, enhancing it with AI and virtual screening capabilities to explore vast chemical spaces.
Recent achievements highlight Gain Therapeutics' impact on the biotech landscape. Data presented at the 20th WORLDSymposium™ showcased the progressive reversal of motor deficits in preclinical models, alongside a significant reduction of neurodegeneration biomarkers. This underscores the potential of GT-02287 as a best-in-class treatment for neurodegenerative diseases.
Gain Therapeutics collaborates with notable organizations including The Michael J. Fox Foundation for Parkinson’s Research and The Silverstein Foundation for Parkinson’s with GBA. These partnerships provide essential support and validation for the company's mission to transform therapeutic landscapes with innovative treatments.
For more information, visit GainTherapeutics.com and follow their updates on LinkedIn.
Gain Therapeutics (Nasdaq: GANX) announced participation at the 12th Annual Jefferies London Healthcare Conference on November 16-19, 2021. CEO Eric Richman will present on November 17 from 9:20 to 9:55 a.m. GMT. Investors can engage in one-on-one meetings either in-person or virtually. The presentation will focus on Gain's innovative drug development strategies targeting neurodegenerative diseases and lysosomal storage disorders through its proprietary SEE-Tx™ platform. For more details, visit Gain’s official website.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that its management team will present at key medical conferences, including The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars on November 10, 2021, and The Society of Neuroscience Annual Meeting on November 9, 2021. The webinars aim to showcase advancements in Parkinson’s research, featuring topics like drug discovery and brain-penetrant allosteric regulators. These sessions will provide insights into ongoing research supported by the foundation. For registration and further information, visit the respective conference websites.
Gain Therapeutics has established a Scientific Advisory Board (SAB) to enhance its research efforts in neurodegenerative diseases and lysosomal storage disorders. Dr. Luca Benatti has been appointed as the chair, joined by esteemed members including Dr. Samuel Broder and Dr. Joanne Taylor. These experts bring decades of significant industry experience to shape the company's clinical strategies as it progresses its lead program in Parkinson’s Disease toward trials. Gain aims to redefine drug discovery through its innovative SEE-Tx™ platform.
Gain Therapeutics, Inc. (Nasdaq: GANX) recently appointed Matthias Alder as Chief Operating Officer to enhance its operational capabilities and prepare for clinical trials of its lead program targeting Gaucher and Parkinson's Diseases, expected in 2022. Alder brings over 25 years of industry experience, previously serving as Chief Business Officer at Autolus Therapeutics. CEO Eric Richman expressed confidence in Alder's ability to scale Gain's platform and expand partnerships. The company focuses on allosteric binding sites using its innovative SEE-Tx™ discovery platform to address neurodegenerative diseases.
Gain Therapeutics, Inc. (Nasdaq: GANX) will participate in the Cantor Virtual Global Healthcare Conference from September 27th-30th, showcasing its innovative approach to targeting allosteric binding sites for neurodegenerative diseases. CEO Eric Richman will present on September 30, from 8:00 to 8:30 a.m. ET, with a webcast available for interested investors. Gain Therapeutics aims to redefine drug discovery using its SEE-Tx™ platform, unlocking new treatment options for challenging disorders.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. The presentation is scheduled for September 22 from 1:15 to 1:55 p.m. ET. Investors can participate via webcast and one-on-one meetings. Gain Therapeutics focuses on optimizing allosteric binding sites in treatments for neurodegenerative diseases.
Gain Therapeutics, focused on neurodegenerative diseases, announced a presentation by Dr. Manolo Bellotto on their allosteric regulators for GM1 Gangliosidosis and Morquio B Disease. The presentation will take place on September 14, 2021, at 2:00 PM PT/5:00 PM ET during the GM1 Virtual Community Conference. These diseases are linked to mutations in the GLB1 gene, leading to toxic substrate accumulation. Gain's STARs aim to potentially treat neurological symptoms, marking a significant advancement in the field.
Gain Therapeutics (Nasdaq: GANX) reported positive topline data from its study on two STAR compounds, GT-02287 and GT-02329, aimed at treating Gaucher Disease and GBA1 Parkinson’s Disease. Conducted at the University of Maryland, the study showed increased GCase protein levels, enhanced enzymatic activity, and decreased α-synuclein in neurons. The company plans to present comprehensive data at an upcoming Michael J. Fox Foundation webinar and initiate IND-enabling studies in Q4 2021, further supporting its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) platform.
Gain Therapeutics (GANX) announced positive topline data from a study on its compounds GT-02287 and GT-02329 for treating Gaucher and GBA1 Parkinson's Disease. The study showed increased GCase protein levels and activity, along with a decrease in toxic α-synuclein levels. Conducted in collaboration with the University of Maryland School of Medicine, findings will be presented in a webinar organized by the Michael J. Fox Foundation. The company plans to initiate IND-enabling studies for these treatments in Q4 2021.
Gain Therapeutics (Nasdaq: GANX), a biotechnology company specializing in neurodegenerative and lysosomal storage disorders, announced that CEO Eric Richman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. An on-demand presentation will be available starting September 13, 7:00 am ET for 90 days. Richman and CFO Salvatore Calabrese are available for virtual 1x1 meetings during the conference. Gain is focused on innovative drug discovery and is supported by organizations like The Michael J. Fox Foundation.
FAQ
What is the current stock price of Gain Therapeutics (GANX)?
What is the market cap of Gain Therapeutics (GANX)?
What is Gain Therapeutics, Inc.?
What diseases is Gain Therapeutics targeting?
What is GT-02287?
How does Gain Therapeutics discover new treatments?
What recent achievements has Gain Therapeutics made?
Who are Gain Therapeutics' partners?
What is the Magellan™ platform?
What is unique about Gain Therapeutics' approach?
How does GT-02287 work?
Where can I find more information about Gain Therapeutics?
